CollaGUARD Adhesion Barrier
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02348541 |
Recruitment Status :
Completed
First Posted : January 28, 2015
Last Update Posted : June 13, 2016
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Hysteroscopic Adhesiolysis | Device: CollaGUARD | Early Phase 1 |
Intrauterine adhesions following gynaecological surgery is a major complication which may cause a range of severe clinical symptoms in women. IUA's can result in menstrual abnormalities, dysmenorrhea and infertility. In pregnancy, adhesions are related to miscarriage, ectopic pregnancy, abnormal placentation, premature labor and delivery and possibly birth defects.
CollaGUARD adhesion barrier is a transparent bioresorbable film approved in Europe for the prevention of postoperative adhesions in patients undergoing abdomino-pelvic laparotomy or laparoscopy.
This study will assess the feasibility of using CollaGUARD adhesion device in hysteroscopic surgery.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 9 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Prevention |
Official Title: | A Post-Market Clinical Follow-up Study to Investigate the Usability of the CollaGUARD Adhesion Barrier Following Hysteroscopic Adhesiolysis |
Study Start Date : | December 2014 |
Actual Primary Completion Date : | September 2015 |
Actual Study Completion Date : | September 2015 |
Arm | Intervention/treatment |
---|---|
CollaGUARD |
Device: CollaGUARD |
- Feasibility of using CollaGUARD in hysteroscopic adhesiolysis: Surgeon completed questionnaire [ Time Frame: following initial hysteroscopy ]surgeon completed questionnaire
- Number of de novo adhesion and adhesion reformation [ Time Frame: 9 weeks post initial hysteroscopy ]assessed during follow-up hysteroscopy
- Change in severity of adhesions [ Time Frame: 9 weeks post initial hysteroscopy ]European Society Gynecological Endoscopy (ESGE) classification of IUA's; modified American Fertility Society (mAFS)
- Degradation of CollaGUARD [ Time Frame: 2 weeks post initial hysteroscopy ]assessed via ultrasound

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 45 Years (Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Diagnosed with intrauterine adhesions and found eligible for hysteroscopic adhesiolysis
- Willing to use additional contraception throughout study
Exclusion Criteria:
- Be pregnant or having a suspected molar pregnancy, lactating, or planning to become pregnant at any time during the study
- Has suffered or currently suffers from a gynaecological malignancy
- Has undergone a previous hysteroscopic surgery (such as removal of fibroids)

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02348541
Netherlands | |
Sint Lucas Andreas Ziekenhuis | |
Amsterdam, Netherlands | |
Spaarne Ziekenhuis | |
Hoofddorp, Netherlands |
Study Director: | David Prior, PhD | Sponsor GmbH |
Responsible Party: | Innocoll |
ClinicalTrials.gov Identifier: | NCT02348541 |
Other Study ID Numbers: |
INN-CG-001 |
First Posted: | January 28, 2015 Key Record Dates |
Last Update Posted: | June 13, 2016 |
Last Verified: | June 2016 |
Tissue Adhesions Cicatrix Fibrosis Pathologic Processes |